Loading…
Cardiovascular Disease Early Detection and Prevention Act of 2026
Legislative Progress
Introduced
April 14, 2026
Latest Action
April 14, 2026
Primary Sponsor
Sheila Cherfilus-McCormickDemocratic(FL)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2026 · third_quarter · Health Issues
Tracking federal policy relating to heart health, related diseases, treatments, research and development and access to care; Legislation includes the Safe Step Act; issues related to the modernization of the Organ Procurement and Transplantation Network (OPTN), Medicare coverage of anti-obesity medications (AOMs), pharmacy benefit manager (PBM) reform, Medicares drug price negotiation program; Maintaining Investments in New Innovation (MINI) Act (H.R. 1672); Womens Heart Health Expansion Act of 2026 (H.R. 7417/S; 3944); and Cardiovascular Disease Early Detection and Prevention Act (H.R. 8260).
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Budget/Appropriations
HR 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act 2027; Section 766, related to provisions regarding the regulation of tobacco products and provisions to address and prohibit the importation and sale of illicit flavored, disposable electronic nicotine delivery system (ENDS) products HR 9310: Department of Homeland Security Appropriations Act 2027; potential provisions related to tobacco and nicotine products HR 8260/S 2587: Departments of Labor, Health and Human Services and Education and Related Agencies Appropriations Act 2027; potential provisions related to tobacco and nicotine products HR 8845/S 2354: Commerce Justice Science and Related Agencies Appropriations Act 2027; potential provisions related to tobacco and nicotine products HR 8495: Financial Services and General Government Appropriations Act, 2027; related to provisions to address and prohibit the importation and sale of illicit flavored, disposable electronic nicotine delivery system (ENDS) products HR 8595: National Security, Department of State, and Related Programs Appropriations Act, 2027; related to provisions to address and prohibit the importation and sale of illicit flavored, disposable electronic nicotine delivery system (ENDS) products HR 9170: Transportation Housing and Urban Development and Related Agencies Appropriations Act 2027; potential provisions related to tobacco and nicotine products HR 6938: FY2026 Consolidated Commerce Justice Science, Energy & Water, Interior Appropriations Act; provisions related to contraband vapor products and the Organized Crime Drug Enforcement Task Force S 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act 2027; potential provisions related to tobacco and nicotine products
Client expense: $3,200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Tracking federal policy relating to heart health, related diseases, treatments, research and development and access to care; Legislation includes the Safe Step Act; issues related to the modernization of the Organ Procurement and Transplantation Network (OPTN), Medicare coverage of anti-obesity medications (AOMs), pharmacy benefit manager (PBM) reform, Medicares drug price negotiation program; Maintaining Investments in New Innovation (MINI) Act (H.R. 1672); Womens Heart Health Expansion Act of 2026 (H.R. 7417/S; 3944); and Cardiovascular Disease Early Detection and Prevention Act (H.R. 8260).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE